The industry says it keeps down the cost of prescription drugs, but critics say it's profiting at the expense of patients.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

But for all the noise, many Wall Street professionals believe the policy risk in the healthcare sector is lower than feared. ...

These include, but are not limited to, the big three drug middlemen known as pharmacy benefit managers (PBMs). According to ...

The companies raised prices a median 4%, though some drugs will cost thousands of dollars more.

Columbus joins the states of Arkansas, California, Kansas, Kentucky, Minnesota and Mississippi and other cities and counties ...

A proposed Arkansas law would forbid pharmacy benefit managers (PBMs) from holding or acquiring interest in retail pharmacy ...

Denouncing the $557 billion industry as “horrible middlemen,” responsible for—and “rich as hell” from— America’s incomparably high prescription drug prices, Trump vowed to get rid of ...